VisMederi is pleased to announce its inclusion in the distinguished 2023 list of the 300 fastest-growing companies, published by the Financial Times in partnership with Statista. VisMederi is proud to be ranked #188 among the leading organizations that have made great gains in growth and innovation over the last decade.
Every year, this index recognizes organizations across Europe that stand out for their resilience, creative initiatives, and strategic growth. This year’s list contains only 55 Italian enterprises, making our inclusion all the more noteworthy. This distinction reinforces VisMederi’s dedication to excellence in scientific research, vaccination testing, and global health initiatives.
A decade of innovation and growth.
Being recognized one of Europe’s fastest-growing companies reflects the devotion of our entire team, who continue to progress our aim of supporting immunology, public health, and vaccine research. VisMederi has evolved over the last decade from a targeted research program to a prominent leader in the field, contributing to key global health projects and collaborative research activities that benefit communities worldwide.
Moving Forward with Purpose and Vision.
As we celebrate this accomplishment, we acknowledge that it is both a milestone and a source of incentive. VisMederi remains committed to providing scientific excellence and forming meaningful relationships to support public health solutions. Our placement in the Financial Times and Statista rankings confirms our commitment to being at the forefront of scientific advances in immunology and vaccination research.
For additional information: https://lnkd.in/dAYUtyjn
